Leadership Overview
Lilly has 10 executives leading key functions including marketing, information technology, finance, operations, and clinical development.
Driven by research and innovation, Lilly is dedicated to discovering, developing, manufacturing, and commercializing prescription medicines to improve global health outcomes.
Driven by research and innovation, Lilly is dedicated to discovering, developing, manufacturing, and commercializing prescription medicines to improve global health outcomes.
Leadership Roles at Lilly
William Torres - Chief Financial Officer & Finance Administrative Manager
William Torres, the Chief Financial Officer & Finance Administrative Manager at Lilly, directs the company's financial strategy and oversees all fiscal operations. This executive role encompasses financial planning, budgeting, forecasting, and ensuring compliance with regulatory requirements across global markets. Torres manages the finance department, guiding investment decisions and optimizing resource allocation to support Lilly's research and development pipeline. The Finance Administrative Manager function ensures the efficient administration of financial processes and controls. By providing critical financial insights and strategic guidance, William Torres plays a pivotal role in driving profitability and sustainable growth. This leadership position is essential for maintaining the financial health of the organization and supporting its long-term objectives in the biopharmaceutical sector.
Brandi Doyle - Vice President and COO- Lilly Cardiometabolic Health Development
Brandi Doyle, the Vice President and COO- Lilly Cardiometabolic Health Development at Lilly, leads the operational execution of development programs within the cardiometabolic health therapeutic area. This executive position involves overseeing the entire development lifecycle, from early-stage research through clinical trials and regulatory submission. Doyle directs cross-functional teams responsible for project management, resource allocation, and ensuring adherence to timelines and quality standards. The Chief Operating Officer role focuses on optimizing development processes to accelerate the delivery of innovative treatments for cardiovascular and metabolic diseases. By driving operational excellence, Brandi Doyle ensures that Lilly's pipeline advancements in cardiometabolic health progress efficiently and effectively, ultimately aiming to improve patient outcomes globally. This leadership is critical for bringing new therapies to market.
Wayne Russo - LoxoLilly Field Chief Operating Officer
Wayne Russo, the LoxoLilly Field Chief Operating Officer at Lilly, spearheads operational strategies for the Loxo Oncology business unit, focusing on field operations and market execution. This senior leadership role involves managing the commercial and operational aspects of Loxo's innovative oncology portfolio within specific geographic regions. Russo directs teams responsible for market access, supply chain logistics, and field force effectiveness, ensuring seamless integration of Loxo's specialized cancer therapies into the broader Lilly network. The Chief Operating Officer function drives operational efficiency and strategic alignment to maximize market penetration and patient reach. By overseeing field operations, Wayne Russo directly contributes to expanding Lilly's impact in oncology, ensuring that cutting-edge treatments are available to patients who need them. This role is crucial for translating scientific breakthroughs into tangible patient benefits.
Scott Booziotis - Executive Director - Early Phase Oncology Medical Affairs, Chief Operating Officer
Scott Booziotis, the Executive Director - Early Phase Oncology Medical Affairs, Chief Operating Officer at Lilly, directs operational strategies for early-phase oncology medical affairs and oversees critical operational functions. This senior role involves managing the execution of medical affairs strategies, ensuring efficient resource allocation for clinical research, and supporting the development of innovative oncology treatments. Booziotis leads teams focused on medical strategy implementation, data generation, and scientific exchange within the early-phase oncology space. The Chief Operating Officer aspect of this position ensures operational excellence and seamless execution of medical affairs activities. By driving operational efficiency and strategic alignment, Scott Booziotis directly contributes to advancing Lilly's oncology pipeline and enhancing its medical affairs capabilities globally. This leadership is vital for translating scientific insights into patient benefit.
Carey Dilts - Executive Director- Chief Operating Officer Diabetes and Obesity Global Medical Affairs
Carey Dilts, the Executive Director- Chief Operating Officer Diabetes and Obesity Global Medical Affairs at Lilly, leads operational execution for global medical affairs strategies focused on diabetes and obesity. This executive role involves overseeing the implementation of medical affairs plans, ensuring efficient resource management, and driving strategic initiatives across international markets. Dilts directs teams responsible for medical communication, evidence generation, and stakeholder engagement within the diabetes and obesity therapeutic areas. The Chief Operating Officer function ensures operational excellence and seamless coordination of global medical affairs activities. By optimizing operational processes and strategic alignment, Carey Dilts directly contributes to advancing Lilly's leadership in addressing diabetes and obesity, ultimately aiming to improve patient care and outcomes worldwide. This leadership is crucial for effective market engagement.
Karen Lockwood - Executive Director Launch Chief Operating Officer Diabetes and Obesity Global Medical Affairs
Karen Lockwood, the Executive Director Launch Chief Operating Officer Diabetes and Obesity Global Medical Affairs at Lilly, spearheads operational readiness and execution for product launches within the diabetes and obesity global medical affairs domain. This critical role involves managing the complex operational aspects of bringing new therapies to market, ensuring seamless coordination across multiple functions. Lockwood directs teams responsible for launch planning, cross-functional alignment, and operational execution to support successful market introductions. The Chief Operating Officer function ensures that all launch-related medical affairs activities are efficiently managed and strategically aligned with company objectives. By driving operational excellence in launch activities, Karen Lockwood directly contributes to expanding Lilly's portfolio and impact in addressing diabetes and obesity, ensuring timely patient access to innovative treatments.
Stephanie Brennan - Global Chief Operating Officer, Medical Affairs, Immunology Heor
Stephanie Brennan, the Global Chief Operating Officer, Medical Affairs, Immunology Heor at Lilly, directs operational strategies for global medical affairs, with a specific focus on Health Economics and Outcomes Research (HEOR) within the immunology therapeutic area. This senior leadership position involves overseeing the operational execution of medical affairs initiatives, ensuring efficient resource allocation, and driving strategic alignment across global HEOR activities. Brennan leads teams responsible for operationalizing medical strategies, managing data generation, and supporting the value demonstration of Lilly's immunology portfolio. The Chief Operating Officer function ensures operational excellence and seamless integration of HEOR insights into medical affairs planning. By optimizing operational processes, Stephanie Brennan directly contributes to advancing Lilly's leadership in immunology and demonstrating the value of its therapies to patients and healthcare systems worldwide.
Karolina Patocki - Head Chief Marketing Officer, Lilly & Oncology Business Unit (Canada)
Karolina Patocki, the Head Chief Marketing Officer, Lilly & Oncology Business Unit (Canada) at Lilly, directs all marketing initiatives for the oncology sector within the Canadian market. This leadership role involves crafting and executing comprehensive marketing strategies to enhance patient access to critical oncology treatments. Patocki oversees the development of promotional campaigns, market analysis, and brand positioning, ensuring alignment with Lilly's global oncology objectives. The Chief Marketing Officer drives market penetration by identifying unmet patient needs and communicating the value proposition of Lilly's innovative therapies. By collaborating with cross-functional teams, including sales and medical affairs, Karolina Patocki ensures a cohesive approach to market engagement and commercial success in Canada's competitive biopharmaceutical landscape. This strategic oversight contributes directly to expanding Lilly's reach and impact in addressing cancer.
Elizabeth van Gelder - Senior Director, Information Technology & Business Units & Special Projects Chief of Staff
Elizabeth van Gelder, the Senior Director, Information Technology & Business Units & Special Projects Chief of Staff at Lilly, manages critical information technology functions and provides strategic support across various business units. This role involves overseeing special projects, ensuring seamless integration of IT solutions with business objectives, and acting as a key liaison between technology departments and operational teams. Van Gelder's responsibilities include driving digital transformation initiatives and optimizing IT infrastructure to support Lilly's global operations. The Chief of Staff function ensures efficient project execution and facilitates communication across diverse teams, enhancing overall operational agility. By focusing on strategic IT alignment and project management, Elizabeth van Gelder directly supports the company's mission of developing and commercializing innovative medicines. This leadership position is vital for maintaining technological advancement and operational efficiency within the organization.
Jonee Drake - Director, Clinical Development Chief of Staff and LRL IDS Portfolio Operations and
Jonee Drake, the Director, Clinical Development Chief of Staff and LRL IDS Portfolio Operations and at Lilly, provides critical operational and strategic support for clinical development initiatives, particularly within the Lilly Research Laboratories (LRL) and Integrated Data Sciences (IDS) portfolios. This leadership position involves managing complex project operations, ensuring efficient resource deployment, and facilitating communication across diverse scientific and operational teams. Drake's responsibilities include overseeing portfolio operations, driving process improvements, and supporting the strategic objectives of clinical development programs. The Chief of Staff role ensures alignment and execution of key initiatives, enhancing the overall productivity of the development teams. By managing critical operational aspects, Jonee Drake directly contributes to the advancement of Lilly's drug development pipeline, supporting the company's commitment to bringing life-changing medicines to patients worldwide.
Explore Leadership Teams in Manufacturing
Astellas Pharma is engaged in the manufacturing, marketing, import, and export of pharmaceuticals. It is headquartered in Tokyo, Japan.
Company Leadership
SY
RT
Bausch Health Companies Inc. operates as a global pharmaceutical and healthcare products company focused on developing, manufacturing, and marketing a broad portfolio of branded pharmaceuticals, generic medicines, over-the-counter healthcare products, and medical devices. The organization works to improve patient health outcomes by delivering therapeutic solutions across multiple medical specialties. Through its research, development, and commercial operations, the company serves healthcare providers, hospitals, pharmacies, and patients across numerous international markets. The company functions as a diversified healthcare enterprise with business segments that address several therapeutic and medical device categories. Its core focus areas include gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and ophthalmology. By maintaining a broad therapeutic portfolio, the organization supports healthcare professionals in diagnosing, managing, and treating a wide range of medical conditions that affect millions of patients globally.
Company Leadership
TU
JS
American Regent, Inc, a Daiichi Sankyo Group Company, develops, manufactures, and supplies high quality sterile injectables for healthcare providers, clinics and hospitals across the United States and Canada. We have locations in New York, Ohio, and Pennsylvania and sales territories nationwide.
Company Leadership
RT
JB
Founded in 1954 and headquartered in Suresnes, France, Servier international is an independent pharmaceutical company governed by a non-profit foundation. Their three research centres are continuously involved in creating, testing, and developing new medicinal products, which are manufactured and packaged in their production centres around the world.
Company Leadership AK
VT
KP
Frequently Asked Questions Regarding Lilly Top Executives and Leadership Team
Unlock more people and company data
